The value of clopidogrel versus aspirin in reducing atherothrombotic events: The CAPRIE study

@article{DurandZaleski2004TheVO,
  title={The value of clopidogrel versus aspirin in reducing atherothrombotic events: The CAPRIE study},
  author={Isabelle Durand-Zaleski and Michel Bertrand},
  journal={PharmacoEconomics},
  year={2004},
  volume={22},
  pages={19-27}
}
Atherothrombotic disease is a growing health problem, and is increasingly more costly to manage. Clopidogrel is an advanced, specific adenosine diphosphate receptor antagonist, which has been shown to be a highly potent antiplatelet agent. Data from the Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events (CAPRIE) study have demonstrated the significantly superior clinical benefit of clopidogrel over aspirin for secondary prevention of atherothrombotic disease, with a relative… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

Clopidogrel versus Aspirin in Patients with Atherothrombosis

  • Applied Health Economics and Health Policy
  • 2012
VIEW 5 EXCERPTS
CITES RESULTS
HIGHLY INFLUENCED

References

Publications referenced by this paper.
SHOWING 1-10 OF 32 REFERENCES

Economic evaluation of clopidogrel in secondary prevention of atherothrombotic events in Hungary [Abstract

K Borsos, J Nagy, E Belicza
  • Value in Health
  • 2003
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

An economic evaluation of clopidogrel vs. aspirin in secondary prevention of ischemic events in high risk atherothrombotic patients [Abstract

L Annemans, S Gabriel, J Spiesser
  • Value in Health
  • 2003
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

[Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery].

  • Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology
  • 2001
VIEW 3 EXCERPTS
HIGHLY INFLUENTIAL

Cost effectiveness of clopidogrel in the secondary prevention of major cardio 26 Durand-Zaleski & Bertrand & Adis Data Information

R Haldeman, TD Szucs, T. Lüscher
  • BV 2004. All rights reserved
  • 2004

Cost - effectiveness of pravastatin in secondary prevention of coronary heart disease : comparison between Belgium and the United States of a projected risk model

E Muls, E VanGanse, MC Closon
  • Eur Heart J
  • 2003